Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Use of Early Intrathecal Therapy to Manage High-Grade Immune Effector Cell-Associated Neurotoxicity Syndrome. JAMA Oncol 2022 May 01;8(5):773-775

Date

03/11/2022

Pubmed ID

35266965

Pubmed Central ID

PMC8914887

DOI

10.1001/jamaoncol.2022.0070

Scopus ID

2-s2.0-85126591538 (requires institutional sign-in at Scopus site)   17 Citations

Abstract

This case series describes the use of early intrathecal steroid administration to manage high-grade and steroid-refractory immune effector cell-associated neurotoxicity syndrome among patients with B-cell non-Hodgkin lymphoma.

Author List

Zurko JC, Johnson BD, Aschenbrenner E, Fenske TS, Hamadani M, Hari P, Shah NN

Authors

Mehdi H. Hamadani MD Professor in the Medicine department at Medical College of Wisconsin
Parameswaran Hari MD Adjunct Professor in the Medicine department at Medical College of Wisconsin
Bryon D. Johnson PhD Adjunct Professor in the Medicine department at Medical College of Wisconsin
Nirav N. Shah MD Associate Professor in the Medicine department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Humans
Immunotherapy
Immunotherapy, Adoptive
Neurotoxicity Syndromes